{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:21:52Z","timestamp":1783470112808,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08776"],"award-info":[{"award-number":["21K08776"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04415-x","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:55:30Z","timestamp":1778590530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NY-ESO-1 and PD-L1 as biomarkers associated with nivolumab response and outcome in unresectable or recurrent esophageal squamous cell carcinoma: a multicenter biomarker study"],"prefix":"10.1007","volume":"75","author":[{"given":"Shigeto","family":"Nakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Motoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohira","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Akamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4415_CR1","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1097\/CM9.0000000000003420","volume":"137","author":"L Qi","year":"2024","unstructured":"Qi L, Sun M, Liu W et al (2024) Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on GLOBOCAN data. Chin Med J (Engl) 137:3108\u20133116. https:\/\/doi.org\/10.1097\/CM9.0000000000003420","journal-title":"Chin Med J (Engl)"},{"key":"4415_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H et al (2022) The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163:649-658.e2. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.054","journal-title":"Gastroenterology"},{"key":"4415_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074962","volume":"385","author":"N Deboever","year":"2024","unstructured":"Deboever N, Jones CM, Yamashita K et al (2024) Advances in diagnosis and management of cancer of the esophagus. BMJ 385:e074962. https:\/\/doi.org\/10.1136\/bmj-2023-074962","journal-title":"BMJ"},{"key":"4415_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/ags3.12781","volume":"8","author":"Y Kubo","year":"2024","unstructured":"Kubo Y, Igaue S, Utsunomiya D et al (2024) Association between preoperative serum zinc level and prognosis in patients with advanced esophageal cancer in the neoadjuvant treatment era. Ann Gastroenterol Surg 8:595\u2013603. https:\/\/doi.org\/10.1002\/ags3.12781","journal-title":"Ann Gastroenterol Surg"},{"key":"4415_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ags3.12799","volume":"8","author":"C Matsumoto","year":"2024","unstructured":"Matsumoto C, Iwatsuki M, Mitsuura C et al (2024) Textbook outcome contributes to long-term prognosis in elderly patients with esophageal squamous cell carcinoma. Ann Gastroenterol Surg 8:787\u2013794. https:\/\/doi.org\/10.1002\/ags3.12799","journal-title":"Ann Gastroenterol Surg"},{"key":"4415_CR6","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41416-022-01726-5","volume":"126","author":"T Makino","year":"2022","unstructured":"Makino T, Yamasaki M, Tanaka K et al (2022) Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. Br J Cancer 126:1555\u20131562. https:\/\/doi.org\/10.1038\/s41416-022-01726-5","journal-title":"Br J Cancer"},{"key":"4415_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41416-023-02151-y","volume":"128","author":"Y Nose","year":"2023","unstructured":"Nose Y, Makino T, Tatsumi M et al (2023) Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes. Br J Cancer 128:1879\u20131887. https:\/\/doi.org\/10.1038\/s41416-023-02151-y","journal-title":"Br J Cancer"},{"key":"4415_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/SLA.0000000000003129","volume":"271","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Makino T, Yamasaki M et al (2020) The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance. Ann Surg 271:875\u2013884. https:\/\/doi.org\/10.1097\/SLA.0000000000003129","journal-title":"Ann Surg"},{"key":"4415_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/SLA.0000000000002808","volume":"270","author":"T Makino","year":"2019","unstructured":"Makino T, Yamasaki M, Tanaka K et al (2019) Metabolic tumor volume change predicts long-term survival and histological response to preoperative chemotherapy in locally advanced esophageal cancer. Ann Surg 270:1090\u20131095. https:\/\/doi.org\/10.1097\/SLA.0000000000002808","journal-title":"Ann Surg"},{"key":"4415_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10388-024-01056-w","volume":"21","author":"T Makino","year":"2024","unstructured":"Makino T, Nakai S, Momose K et al (2024) Efficacy and survival of nivolumab treatment for recurrent\/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus 21:319\u2013327. https:\/\/doi.org\/10.1007\/s10388-024-01056-w","journal-title":"Esophagus"},{"key":"4415_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10388-025-01176-x","volume":"23","author":"T Makino","year":"2026","unstructured":"Makino T, Nakai S, Hagi T et al (2026) Conversion surgery following immunochemotherapy for initially unresectable\/recurrent esophageal cancer. Esophagus 23:131\u2013138. https:\/\/doi.org\/10.1007\/s10388-025-01176-x","journal-title":"Esophagus"},{"key":"4415_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383456","volume":"15","author":"SA Javed","year":"2024","unstructured":"Javed SA, Najmi A, Ahsan W, Zoghebi K (2024) Targeting PD-1\/PD-L1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front Immunol 15:1383456. https:\/\/doi.org\/10.3389\/fimmu.2024.1383456","journal-title":"Front Immunol"},{"key":"4415_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506\u20131517. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"4415_CR14","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-21-0985","volume":"28","author":"M Okada","year":"2022","unstructured":"Okada M, Kato K, Cho BC et al (2022) Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res 28:3277\u20133286. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0985","journal-title":"Clin Cancer Res"},{"key":"4415_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.62347\/XUWC6412","volume":"14","author":"M Sun","year":"2024","unstructured":"Sun M, Yang P, Wang W (2024) Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma. Am J Cancer Res 14:1981\u20131998. https:\/\/doi.org\/10.62347\/XUWC6412","journal-title":"Am J Cancer Res"},{"key":"4415_CR16","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i8.109489","volume":"17","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang RY, Xu YF et al (2025) Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: insights into the tumor microenvironment and biomarker landscape. World J Gastrointest Oncol 17:109489. https:\/\/doi.org\/10.4251\/wjgo.v17.i8.109489","journal-title":"World J Gastrointest Oncol"},{"key":"4415_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s10388-022-00978-7","volume":"20","author":"Y Matsubara","year":"2023","unstructured":"Matsubara Y, Toriyama K, Kadowaki S et al (2023) The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. Esophagus 20:524\u2013532. https:\/\/doi.org\/10.1007\/s10388-022-00978-7","journal-title":"Esophagus"},{"key":"4415_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2024.152394","volume":"74","author":"Z Chi","year":"2025","unstructured":"Chi Z, Peng L, Karamchandani DM et al (2025) PD-L1 (22C3) expression and prognostic implications in esophageal squamous cell carcinoma. Ann Diagn Pathol 74:152394. https:\/\/doi.org\/10.1016\/j.anndiagpath.2024.152394","journal-title":"Ann Diagn Pathol"},{"key":"4415_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"4415_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41416-020-0975-7","volume":"123","author":"T Hagi","year":"2020","unstructured":"Hagi T, Kurokawa Y, Kawabata R et al (2020) Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer 123:965\u2013972. https:\/\/doi.org\/10.1038\/s41416-020-0975-7","journal-title":"Br J Cancer"},{"key":"4415_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.acc.2022.09.004","volume":"112","author":"K Kurose","year":"2023","unstructured":"Kurose K, Sakaeda K, Fukuda M et al (2023) Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. Adv Clin Chem 112:155\u2013204. https:\/\/doi.org\/10.1016\/bs.acc.2022.09.004","journal-title":"Adv Clin Chem"},{"key":"4415_CR22","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/1759-7714.13834","volume":"12","author":"EH Jung","year":"2021","unstructured":"Jung EH, Jang HR, Kim SH et al (2021) Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer 12:2237\u20132245. https:\/\/doi.org\/10.1111\/1759-7714.13834","journal-title":"Thorac Cancer"},{"key":"4415_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.31083\/j.fbl2809219","volume":"28","author":"L Zhong","year":"2023","unstructured":"Zhong L, Li H, Chang W et al (2023) TP53 mutations in esophageal squamous cell carcinoma. Front Biosci (Landmark Ed) 28:193. https:\/\/doi.org\/10.31083\/j.fbl2809219","journal-title":"Front Biosci (Landmark Ed)"},{"key":"4415_CR24","doi-asserted-by":"publisher","first-page":"3801526","DOI":"10.1155\/2023\/3801526","volume":"2023","author":"Y Jin","year":"2023","unstructured":"Jin Y, Zhao X, Song X et al (2023) The high expression of p53 is predictive of poor survival rather than TP53 mutation in esophageal squamous cell carcinoma. J Oncol 2023:3801526. https:\/\/doi.org\/10.1155\/2023\/3801526","journal-title":"J Oncol"},{"key":"4415_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10388-025-01120-z","volume":"22","author":"S Nakai","year":"2025","unstructured":"Nakai S, Makino T, Momose K et al (2025) Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable\/recurrent esophageal squamous cell carcinoma. Esophagus 22:360\u2013372. https:\/\/doi.org\/10.1007\/s10388-025-01120-z","journal-title":"Esophagus"},{"key":"4415_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4415_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","volume":"273","author":"S Urakawa","year":"2021","unstructured":"Urakawa S, Makino T, Yamasaki M et al (2021) Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg 273:1141\u20131149. https:\/\/doi.org\/10.1097\/SLA.0000000000003445","journal-title":"Ann Surg"},{"key":"4415_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/SLA.0000000000004238","volume":"275","author":"T Hagi","year":"2022","unstructured":"Hagi T, Makino T, Yamasaki M et al (2022) Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery. Ann Surg 275:1121\u20131129. https:\/\/doi.org\/10.1097\/SLA.0000000000004238","journal-title":"Ann Surg"},{"key":"4415_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/SLA.0000000000005104","volume":"277","author":"T Noma","year":"2023","unstructured":"Noma T, Makino T, Ohshima K et al (2023) Immunoscore signatures in surgical specimens and tumor-infiltrating lymphocytes in pretreatment biopsy predict treatment efficacy and survival in esophageal cancer. Ann Surg 277:528\u2013537. https:\/\/doi.org\/10.1097\/SLA.0000000000005104","journal-title":"Ann Surg"},{"key":"4415_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386:449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"4415_CR31","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"Y Hayashi","year":"2023","unstructured":"Hayashi Y, Makino T, Sato E et al (2023) Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer 128:2175\u20132185. https:\/\/doi.org\/10.1038\/s41416-023-02235-9","journal-title":"Br J Cancer"},{"key":"4415_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","volume":"95","author":"S Gnjatic","year":"2006","unstructured":"Gnjatic S, Nishikawa H, Jungbluth AA et al (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1\u201330. https:\/\/doi.org\/10.1016\/S0065-230X(06)95001-5","journal-title":"Adv Cancer Res"},{"key":"4415_CR33","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-04-0819","volume":"10","author":"S Fujita","year":"2004","unstructured":"Fujita S, Wada H, Jungbluth AA et al (2004) NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 10:6551\u20136558. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0819","journal-title":"Clin Cancer Res"},{"key":"4415_CR34","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","volume":"182","author":"J Fourcade","year":"2009","unstructured":"Fourcade J, Kudela P, Andrade Filho PA et al (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182:5240\u20135249. https:\/\/doi.org\/10.4049\/jimmunol.0803245","journal-title":"J Immunol"},{"key":"4415_CR35","doi-asserted-by":"publisher","first-page":"16723","DOI":"10.1073\/pnas.1110814108","volume":"108","author":"J Yuan","year":"2011","unstructured":"Yuan J, Adamow M, Ginsberg BA et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108:16723\u201316728. https:\/\/doi.org\/10.1073\/pnas.1110814108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4415_CR36","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00262-021-02892-w","volume":"70","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Kageyama S, Miyahara Y et al (2021) Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother 70:3081\u20133091. https:\/\/doi.org\/10.1007\/s00262-021-02892-w","journal-title":"Cancer Immunol Immunother"},{"key":"4415_CR37","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00262-020-02766-7","volume":"70","author":"J Lee","year":"2021","unstructured":"Lee J, Kim B, Jung HA et al (2021) Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect. Cancer Immunol Immunother 70:1203\u20131211. https:\/\/doi.org\/10.1007\/s00262-020-02766-7","journal-title":"Cancer Immunol Immunother"},{"key":"4415_CR38","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2022.3707","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2022) Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol 8:1635\u20131643. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3707","journal-title":"JAMA Oncol"},{"key":"4415_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100154","volume":"36","author":"ME Robert","year":"2023","unstructured":"Robert ME, R\u00fcschoff J, Jasani B et al (2023) High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma. Mod Pathol 36:100154. https:\/\/doi.org\/10.1016\/j.modpat.2023.100154","journal-title":"Mod Pathol"},{"key":"4415_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102768","volume":"15","author":"A Mercier","year":"2023","unstructured":"Mercier A, Conan-Charlet V, Quintin-Rou\u00e9 I et al (2023) Reproducibility in PD-L1 immunohistochemistry quantification through the tumor proportion score and the combined positive score: could dual immunostaining help pathologists? Cancers (Basel) 15:2768. https:\/\/doi.org\/10.3390\/cancers15102768","journal-title":"Cancers (Basel)"},{"key":"4415_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/PAI.0000000000000737","volume":"27","author":"CR Taylor","year":"2019","unstructured":"Taylor CR, Jadhav AP, Gholap A et al (2019) A multi-institutional study to evaluate automated whole slide scoring of immunohistochemistry for assessment of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Appl Immunohistochem Mol Morphol 27:263\u2013269. https:\/\/doi.org\/10.1097\/PAI.0000000000000737","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4415_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/his.14571","volume":"80","author":"S Toivonen","year":"2022","unstructured":"Toivonen S, Rokka A, Ostromohov N et al (2022) Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer. Histopathology 80:693\u2013705. https:\/\/doi.org\/10.1111\/his.14571","journal-title":"Histopathology"},{"key":"4415_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53262-w","volume":"15","author":"K Tanoue","year":"2024","unstructured":"Tanoue K, Ohmura H, Uehara K et al (2024) Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer. Nat Commun 15:9033. https:\/\/doi.org\/10.1038\/s41467-024-53262-w","journal-title":"Nat Commun"},{"key":"4415_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1106434","volume":"13","author":"T Magara","year":"2023","unstructured":"Magara T, Nakamura M, Nojiri Y et al (2023) Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures. Front Oncol 13:1106434. https:\/\/doi.org\/10.3389\/fonc.2023.1106434","journal-title":"Front Oncol"},{"key":"4415_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/cas.15198","volume":"113","author":"K Okadome","year":"2022","unstructured":"Okadome K, Baba Y, Yasuda-Yoshihara N et al (2022) PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Cancer Sci 113:399\u2013410. https:\/\/doi.org\/10.1111\/cas.15198","journal-title":"Cancer Sci"},{"key":"4415_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103137","volume":"63","author":"Y Zou","year":"2021","unstructured":"Zou Y, Hu X, Zheng S et al (2021) Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: a systematic review and meta-analysis. EBioMedicine 63:103137. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103137","journal-title":"EBioMedicine"},{"key":"4415_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102442","volume":"59","author":"B Yu","year":"2025","unstructured":"Yu B, Qi C, Liu Z et al (2025) Spatial heterogeneity of PD-L1 expression influence its assessment in esophageal squamous cell carcinoma. Transl Oncol 59:102442. https:\/\/doi.org\/10.1016\/j.tranon.2025.102442","journal-title":"Transl Oncol"},{"key":"4415_CR48","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3892\/ol.2020.11709","volume":"20","author":"M Niyaz","year":"2020","unstructured":"Niyaz M, Ainiwaer J, Abudureheman A et al (2020) Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance. Oncol Lett 20:1855\u20131865. https:\/\/doi.org\/10.3892\/ol.2020.11709","journal-title":"Oncol Lett"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04415-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04415-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:07:56Z","timestamp":1783469276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04415-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4415"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04415-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.M. has received lecture fees from Ono Pharmaceutical Co., Ltd. and Bristol Myers Squibb. Y.Ku. has received lecture fees and research grants from Ono Pharmaceutical Co., Ltd. and lecture fees from Bristol Myers Squibb. Y.D. has received lecture fees and research grants from Ono Pharmaceutical Co., Ltd. and lecture fees from Bristol Myers Squibb. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all included patients before enrollment, unless the patient had died or been lost to follow-up.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review boards of all participating institutions (approval no. 19146-5).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"182"}}